Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment

Of 40 patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 28 completed a controlled three-month trial of prednisone. Prednisone was shown to cause a small but significant improvement over no treatment in scored neurological disability, some measures of computer-assisted s...

Full description

Saved in:
Bibliographic Details
Published inAnnals of neurology Vol. 11; no. 2; p. 136
Main Authors Dyck, P J, O'Brien, P C, Oviatt, K F, Dinapoli, R P, Daube, J R, Bartleson, J D, Mokri, B, Swift, T, Low, P A, Windebank, A J
Format Journal Article
LanguageEnglish
Published United States 01.02.1982
Subjects
Adolescent
Adult
Chronic Disease
Clinical Trials as Topic
Demyelinating Diseases - drug therapy
Demyelinating Diseases - physiopathology
Female
Humans
Male
Middle Aged
Polyradiculoneuropathy - drug therapy
Polyradiculoneuropathy - physiopathology
Prednisone - administration & dosage
Prednisone - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Of 40 patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 28 completed a controlled three-month trial of prednisone. Prednisone was shown to cause a small but significant improvement over no treatment in scored neurological disability, some measures of computer-assisted sensory detection threshold, graded muscle strength, and some attributes of nerve conduction. No subset of patients was more likely than another to be responsive to prednisone; those with a progressive course were as likely to be responsive as recurrent cases. This finding provides further justification for classifying progressive with recurrent cases as CIDP and demonstrates that prednisone treatment should not be withheld from patients with progressive disease.
ISSN:0364-5134
DOI:10.1002/ana.410110205